INH (450 mg X 300 mg) in some case under DPCO, 1987. Ceiling prices for different pack sizes of this combination formulation are also being notified. Government have not received any reports of non-availability of formulations referred to in the question.

Prices of different salts of Betamethasone

3307. SHRI DHARANIDHAR BASUMATARI: Will the Minister of INDUSTRY be pleased to state:

(a) what are the different salts of Betamethasone which were the subject matter of litigation apart from Betamethasone itself in Delhi High Court and what was the production of each from the date of litigation to the date of promulgation of Drugs Price Control Order, 1987;

(b) what were the prices of formulations charged by the company based on these drugs and those which were approved by Government along with production of each formulation, yearwise;

(c) whether this Ministry made any recovery, if so, on what rate the calculation was made in respect of each bulk drug and formulation; and

(d) what is the present price at which each formulation is being sold and when was the price of each fixed?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The different salts of Betamethasone involved in the Delhi High Court case are:

1. Betamethasone Alcohol
2. Betamethasone 17-Valerate
3. Betamethasone Di-Sodium Phosphate.

The production of Betamothasone during the year 1982 83 to 1985-86 is given below:

Year	Production (Kg.) M/s. Glindia Ltd.
1982-83	583.00
1983-84	613.88
1984-85	712.64
1985-86	735.19

(b) and (d) The details asked for are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

(c) No, Sir.

Assessment of DPEA against drug companies

3308. SHRI DHARANIDHAR BASUMATARI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 641 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) by when the amounts due upto 31st December, 1983 would be finally assessed against the drug companies;

(b) whether it is a fact that a number of irregularities have been committed by the committee in assessing the amount;

(c) by when the final findings of the committee would be laid on the Table of the House; and

(d) what are the details based on which tentative amounts have been assessed?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The special team has already finalised in respect of 6 companies.

(b) No Sir.

(c) The findings of the Committee are not required to be laid on the Table of the House.

(d) The tentative amounts have been assessed based on the prices charged by the companies and the prices fixed by the Government.

Prices of Methidilazine range formulations

3309. SHRI HARI SINGH:
DR. (SHRIMATI) NAJMA HEPTULLA:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 668 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) what are the names of the major formulators of Methidilazine, Nandrolone

Deconate, Hydroxyprogesterone its salts, Sovental Lactate and Tolnafate and what was the price of their formulations under DPCO, 1979 and the present price under DPCO, 1987;

(b) whether the licenced capacity of Glaxo for Methidilazine is 8 tonnes per annum and not 180 tonnes per annum;

(c) what are the imports of these drugs during the last three year, yearwise and their CIF import prices;

(d) what are their sales turn over as per ORG;

(e) whether any company is allowed to manufacture any of these drugs; and

(f) if so, the names of the Companies, licensed capacity of each and stage of manufacture alongwith the production of each during the last three years, yearwise of each producer?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The required details to the extent available are given in the Statement-I.

(b) The licenced capacity of M/s. Glindia for Methidilazine is 180kg per annum.

(c) The required details to the extent available are given in the Statement-II.

(d) Sales turnover is not Monitored.

(e) and (f) The required details to the extent available are given in the Statement-III.

Statement I

Name of the Company/Name of the formulation	Pack size	Earlier price Rs. Ps.	Revised price Rs. Ps.	% age changed
1. M/s. Glindia Ltd.				
i. Dilosyn Syrup (Methdilazine)	120 ml.	6.04	10.44	+72.8
ii. Dioloxyn Expectorant (Methdilazine)	Do	5.03	9.53	+89.5
iii. -do-	450 ml.	13.61	23.0.	469.0
2. M/s. German Remedies				
i. Proluton Depot 500 mg. Amps. (Hydroxy Progesterone)	5x2 ml.	175.00 (as claimed by the Company)	187.50	+7.14

Statement-II

(Rs. in lakhs)

Sl. No.	Name of the drug	Unit	1984-85 qty.	1984-85 CIF value Rs.	1985-86 Qty.	1985-86 CIF value Rs.	1986-87 Qty I	1986-87 CIF value Rs.
1.	Hydroxy Progesterone	Kg.	10	0.15	3	0.18	13	0.92
2.	Tolnafate	Kg.	632	87.26	595	59.57	918	122.73
3.	Nandrolone Deconate	Kgs.	3	0.27	10	0.97	14.5	1.75

Statement III

Name of drug/company	A/c. Unit	Capacity
Methidilazine	Kgs.	180
Glindia Ltd.		180
Sovental Lactate	Kgs.	
Boehringer-Knoll Ltd.		820.05
Tolnaftate	Kgs.	
1 Unichem Labs.		100
2 Reckitt & Colman		1000
3 Nila Products		3000

Price increase of various packs of formulations

3310. SHRI HARI SINGH:
DR. (SHRIMATI) NAJMA HEPTULLA:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 683 given in the Rajya Sabha on 2nd May, 1988 and state:

(a) what were the prices of various packs of Dilosyn, Equagesic, Voveren, Pregnidoxin, Codein Linctus under DPCO, 1979 and when were they approved;

(b) what are the present prices of these products and what is the percentage increase;

(c) what is the sales turnover of each as per the latest ORG;

(d) what are the names of the other producers having identical products; and

(e) the names of the products which are under price decontrol?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The required details to the extent available are given in the Statement. (*See* below)

(c) and (d) Sales turnover is not monitored.

(e) As per the provisions of DPCO, 1987 and guidelines issued thereunder among referred formulations only equagesic Tablets are under price control.

Statement

S.No.	Name of the Co./Name of the formulation	Pack size	Earlier Price	Revised Price	%age changed
1	*Glindia*				
	(i) Dilosyn Expectorant	450 ml	27.74	23.00*	– 17.1
	(ii) Do.	120 ml	5.03	9.53	89.5
	(iii) Dilosyn Syrup	120 ml	6.04	10.44	72.8

*reduced with Govt. intervention.